Type 2 diabetes (T2DM) is a prevalent disease involving several clinical implications including, renal, vascular, and metabolic complications. Therapies focusing on glycemic control in T2DM have largely failed in substantial improvement in cardiovascular and kidney outcomes. This has accentuated the need for new treatment strategies for reno-CV protection in T2DM patients. 1 In recent years, compelling evidence is available for new-age antidiabetic drugs; the sodium-glucose co-transporter 2 (SGLT2) inhibitors demonstrating cardioprotective and renoprotective effects.
2 In this regard, Boehringer Ingelheim India and Docplexus have organized a panel discussion on 22 nd January 2021 from 03:00 PM IST onwards. In this webinar, the expert panel will discuss the renal-vascular-metabolic Conundrum in T2DM and the lessons learned with SGLT2-i. We invite you to share your questions which will be…
